P. Kosmidis

9.5k total citations · 2 hit papers
224 papers, 6.4k citations indexed

About

P. Kosmidis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, P. Kosmidis has authored 224 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Oncology, 95 papers in Pulmonary and Respiratory Medicine and 56 papers in Surgery. Recurrent topics in P. Kosmidis's work include Lung Cancer Treatments and Mutations (64 papers), Cancer Treatment and Pharmacology (45 papers) and Colorectal Cancer Treatments and Studies (38 papers). P. Kosmidis is often cited by papers focused on Lung Cancer Treatments and Mutations (64 papers), Cancer Treatment and Pharmacology (45 papers) and Colorectal Cancer Treatments and Studies (38 papers). P. Kosmidis collaborates with scholars based in Greece, United States and Germany. P. Kosmidis's co-authors include Dimitrios Bafaloukos, George Fountzilas, Helena Linardou, Samuel Murray, Issa J Dahabreh, Dimosthenis Skarlos, George Nasioulas, John K. Triantafillidis, Christos Papadimitriou and Fotios Siannis and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

P. Kosmidis

223 papers receiving 6.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

2004 678 citations P. Kosmidis et al. profile →
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 596 citations Helena Linardou, Issa J Dahabreh et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
P. Kosmidis	3.9k	2.3k	1.2k	1.0k	817	224	6.4k
Ashley E. Winkler	3.9k 1.0×	2.5k 1.1×	1.1k 1.0×	1.4k 1.4×	848 1.0×	12	7.3k
Gabriela Kornek	3.7k 1.0×	1.7k 0.7×	821 0.7×	1.6k 1.5×	834 1.0×	161	6.3k
A. B. Miller	3.6k 0.9×	2.4k 1.0×	965 0.8×	1.4k 1.3×	774 0.9×	6	6.8k
R. Swindell	2.3k 0.6×	1.8k 0.8×	848 0.7×	1.5k 1.5×	997 1.2×	166	6.1k
Paul S. Ritch	2.9k 0.7×	1.7k 0.7×	625 0.5×	1.2k 1.2×	720 0.9×	133	4.6k
M. Schneider	2.8k 0.7×	1.3k 0.5×	1.0k 0.9×	811 0.8×	316 0.4×	108	5.8k
Keun‐Wook Lee	4.0k 1.0×	3.3k 1.4×	1.3k 1.1×	2.0k 1.9×	676 0.8×	265	7.3k
Lee S. Rosen	8.4k 2.1×	3.8k 1.6×	3.6k 3.0×	1.8k 1.7×	1.1k 1.3×	232	12.1k
Aristotelis Bamias	3.1k 0.8×	2.2k 1.0×	1.7k 1.4×	1.9k 1.9×	829 1.0×	276	6.9k
Claire F. Verschraegen	3.0k 0.8×	1.5k 0.7×	2.0k 1.6×	1.1k 1.0×	671 0.8×	267	6.9k

Countries citing papers authored by P. Kosmidis

Since Specialization

Citations

This map shows the geographic impact of P. Kosmidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kosmidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kosmidis more than expected).

Fields of papers citing papers by P. Kosmidis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kosmidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kosmidis. The network helps show where P. Kosmidis may publish in the future.

Co-authorship network of co-authors of P. Kosmidis

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kosmidis. A scholar is included among the top collaborators of P. Kosmidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kosmidis. P. Kosmidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Linardou, Helena, Kyriaki Papadopoulou, Nikolaos Korfiatis, et al.. (2023). 1435P Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis. Annals of Oncology. 34. S816–S817. 1 indexed citations

Dimitrakopoulos, Foteinos‐Ioannis, Georgia-Angeliki Koliou, Vassiliki Kotoula, et al.. (2021). Genetic Variation in the Vascular Endothelial Growth Factor (VEGFA) Gene at rs13207351 Is Associated with Overall Survival of Patients with Head and Neck Cancer. Cancers. 13(5). 1163–1163. 4 indexed citations

Tsiatas, Marinos, Konstantine T. Kalogeras, Kyriaki Manousou, et al.. (2018). Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy. Cancer Medicine. 7(10). 5066–5082. 8 indexed citations

Boukovinas, I., Vassilis Georgoulias, P. Kosmidis, et al.. (2015). The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece. Value in Health. 18(7). A451–A451. 1 indexed citations

Kotoula, Vassiliki, Mattheos Bobos, Maria Vassilakopoulou, et al.. (2014). Intact or Broken-apart RNA. Applied immunohistochemistry & molecular morphology. 23(1). 60–70. 4 indexed citations

Kosmidis, P., George Fountzilas, Anastasia G Eleftheraki, et al.. (2010). Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Annals of Oncology. 22(4). 827–834. 12 indexed citations

Nackaerts, Kristiaan, Corey J. Langer, Peter Harper, et al.. (2008). International Consensus Panel Recommendations for the diagnosis of bone metastases (METS) from lung cancer (LC). Journal of Thoracic Oncology. 3(4). 4 indexed citations

Fountzilas, George, Mattheos Bobos, Anna Kalogera‐Fountzila, et al.. (2008). Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. Cancer Investigation. 26(8). 784–793. 54 indexed citations

Murray, Samuel, Issa J Dahabreh, Helena Linardou, et al.. (2008). Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database. Journal of Thoracic Oncology. 3(8). 832–839. 116 indexed citations

10.

Kosmidis, P., Meletios Α. Dimopoulos, Konstantinos Syrigos, et al.. (2007). Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Thoracic Oncology. 2(2). 135–140. 31 indexed citations

11.

Kosmidis, P., Haralabos P. Kalofonos, C. Christodoulou, et al.. (2007). Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 19(1). 115–122. 46 indexed citations

12.

Mauri, Davide, George Pentheroudakis, D. Bafaloukos, et al.. (2006). Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.. PubMed. 26(4B). 3175–81. 43 indexed citations

13.

Aravantinos, Gerasimos, George Fountzilas, P. Kosmidis, et al.. (2005). Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Annals of Oncology. 16(7). 1116–1122. 18 indexed citations

14.

Xiros, Nikolaos I., Theofanis Economopoulos, G.F. Samelis, et al.. (2005). Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Annals of Oncology. 16(5). 773–779. 13 indexed citations

15.

Kalofonos, Haralabos P., Gerasimos Aravantinos, P. Kosmidis, et al.. (2005). Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Annals of Oncology. 16(6). 869–877. 62 indexed citations

16.

Fountzilas, George, George P. Stathopoulos, George Kouvatseas, et al.. (2004). Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients With Breast Cancer and One to Nine Infiltrated Nodes. American Journal of Clinical Oncology. 27(1). 57–67. 1 indexed citations

17.

Fountzilas, George, D. Tsavdaridis, Anna Kalogera‐Fountzila, et al.. (2001). Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. Annals of Oncology. 12(11). 1545–1551. 61 indexed citations

18.

Tsavaris, N., D. Skarlos, Gerasimos Aravantinos, et al.. (2000). Combined Treatment with Low-Dose Interferon plus Vinblastine Is Associated with Less Toxicity Than Conventional Interferon Monotherapy in Patients with Metastatic Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 20(8). 685–690. 5 indexed citations

19.

Dimopoulos, Meletios Α., Vassilis Georgoulias, Christos Papadimitriou, et al.. (1999). Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology. 10(11). 1385–1388. 52 indexed citations

20.

Tsavaris, Νicolas, et al.. (1991). Decreased Oral Toxicity with the Local Use of Allopurinol in Patients Who Received High Dose 5-Fluorouracil. PubMed. 7(3). 113–117. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact